跳至主要内容
临床试验/NCT05701956
NCT05701956已完成3 期

Intravenous Tenecteplase Plus Endovascular Thrombectomy Versus Endovascular Thrombectomy Alone on 4.5 to 24 Hours After Stroke Due to Basilar Artery Occlusion -a Multicenter, Randomized Controlled, Clinical Trial

The First Affiliated Hospital of University of Science and Technology of China1 个研究点 分布在 1 个国家目标入组 330 人开始时间: 2023年3月16日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
330
试验地点
1
主要终点
Proportion of patients with modified Rankin Score 0-2 at day 90 (±14 days)

研究概览

简要总结

To assess the effect of intravenous tenecteplase plus endovascular thrombectomy (EVT) compared to EVT alone on 4.5 to 24 hours after stroke due to basilar artery occlusion.

详细描述

Background and Rationale: Recently, two prospective multicenter RCT (ATTENTION and BAOCHE trials) have shown a significantly beneficial effect of EVT in patients with an acute symptomatic basilar artery occlusion. The EXTEND-IA TNK trial demonstrated that intravenous thrombolysis with tenecteplase is superior to alteplase before EVT for anterior circulation large vessel occlusion strokes. However, it is unclear whether intravenous tenecteplase bridging with EVT is superior to EVT alone in the extended window patients with basilar artery occlusion. Therefore, additional studies are needed to explore the potential benefit of intravenous tenecteplase in these patients.

Study design: Multicenter, prospective, controlled clinical trial with open-label treatment and blind outcome assessment (PROBE) of intravenous tenecteplase plus EVT versus EVT alone. The trial has observer blinded assessment of the primary outcome and neuroimaging at baseline and follow up.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients presenting with posterior circulation ischemic stroke symptoms due to basilar artery occlusion or vertebral artery occlusions that prevent antegrade flow into the basilar artery;
  • Time from stroke onset to randomization within 4.5-24 hours of estimated time of basilar artery occlusion;
  • Patient's age≥18 years;
  • Presence of basilar artery or vertebral artery occlusion, confirmed by CT Angiography (CTA), MR Angiography (MRA) or Digital Subtraction Angiography (DSA). In cases of vertebral artery occlusion, the occlusion must completely prevent antegrade flow into the basilar artery;
  • Patients presenting with acute ischemic stroke eligible using standard criteria (except for time window) to receive both endovascular thrombectomy and intravenous thrombolysis;
  • Baseline National Institutes of Health Stroke Scale (NIHSS) score≥ 10 at the time of neuroimaging;
  • The patient or patient's legal representative signs the informed consent form.

排除标准

  • CT or MR evidence of intracerebral hemorrhage (the presence of < 10 microbleeds is allowed);
  • Pre-stroke modified Rankin scale (mRS) score of ≥ 2;
  • Posterior circulation Acute Stroke Prognosis Early CT Score (PC-ASPECTS) on CT/ CTA-Source Images<6; PC-ASPECTS on magnetic resonance imaging-diffusion weighted imaging (MRI-DWI) <5;
  • Pregnant or lactating women;
  • Allergy to contrast agent or nitinol alloy;
  • Life expectancy<1 year;
  • CTA/MRA/DSA show vascular tortuosity, vascular variation or artery dissection, which would make it difficult to perform endovascular treatment;
  • Participating in other clinical trials;
  • Systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg, which cannot be controlled by antihypertensive drugs;
  • Genetic or acquired hemorrhagic diathesis, lack of anticoagulant factor; or oral anticoagulant with international normalized ratio (INR) > 1.7, or novel oral anticoagulant within prior 48 hours;
  • Blood glucose <50 mg/dl (2.8 mmol/L) or >400 mg/dl (22.2 mmol/L), platelet< 100*109/L;
  • Renal insufficiency defined as serum creatinine >2.0 mg/dl (or 176.8 μ mol/l) or a glomerular filtration rate <30 mL/min or the need for hemodialysis or peritoneal dialysis;
  • Patients who cannot complete 90-day follow-up (such as patients without fixed residence, overseas patients, etc);
  • The patient has acute ischemic cerebral infarction within 3 months from randomization;
  • The patient had a history of or clinical suspicion for cerebral vasculitis or infectious endocarditis;
  • The patient has nervous system disease or mental disorder before stroke onset, which may affect the assessment of their condition;
  • CT or MR examination showed large cerebellar infarction with obvious space occupying effect and compression of the fourth ventricle;
  • Patients with extensive bilateral thalamic or extensive bilateral brainstem infarction on CT or MR examination;
  • CTA/MRA/DSA show both anterior and posterior circulation large vessel occlusion;
  • Patients with intracranial tumors (except small meningiomas);
  • Patients who received intravenous thrombolytics treatment before the randomization;

研究组 & 干预措施

Intravenous tenecteplase+endovascular thrombectomy

Experimental

Patients will receive intravenous tenecteplase (0.25mg/kg, max 25mg) plus endovascular thrombectomy.

干预措施: Tenecteplase (Drug)

Intravenous tenecteplase+endovascular thrombectomy

Experimental

Patients will receive intravenous tenecteplase (0.25mg/kg, max 25mg) plus endovascular thrombectomy.

干预措施: Endovascular thrombectomy (Procedure)

Endovascular thrombectomy alone

Active Comparator

Patients will receive endovascular thrombectomy alone.

干预措施: Endovascular thrombectomy (Procedure)

结局指标

主要结局

Proportion of patients with modified Rankin Score 0-2 at day 90 (±14 days)

时间窗: 90 (± 14 days) after procedure

modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)

次要结局

  • Successful reperfusion (Extended thrombolysis in cerebral infarction [eTICI] score 2b50-3) on digital substraction angiography (DSA) prior to thrombectomy(within 5 minutes at angiography)
  • Score on the EuroQoL 5-dimensions 5-level (EQ5D-5L) at 90 days (±14 days)(90 (± 14 days) after procedure)
  • Successful recanalization on CT or MR angiography within 72 hours(Within 72 hours after procedure)
  • Infarct volume (Posterior Circulation Acute Stroke Prognosis Early Computed Tomography Score, PC-ASPECTS) evaluated on CT or MRI within 72 hours(Within 72 hours after procedure)
  • Proportion of patients with modified Rankin Score 0-3 at day 90 (±14 days)(90 (± 14 days) after procedure)
  • Ordinal Shift analysis of modified Rankin Score at day 90 (±14 days)(90 (± 14 days) after procedure)
  • Score on the NIHSS at 24 hours(24 hours after procedure)
  • Score on the NIHSS at 5-7 days or discharge(5-7 days or discharge after procedure)
  • Proportion of patients with modified Rankin Score 0-1 at day 90 (±14 days)(90 (± 14 days) after procedure)
  • Proportion of patients with modified Rankin Score 0-4 at day 90 (±14 days)(90 (± 14 days) after procedure)
  • level of activities of daily living (Barthel index, BI) at 90 days (±14 days)(90 (± 14 days) after procedure)
  • Successful reperfusion on final angiography of thrombectomy(Within 5 minutes at final angiography of thrombectomy)

研究者

发起方
The First Affiliated Hospital of University of Science and Technology of China
申办方类型
Other
责任方
Principal Investigator
主要研究者

Wei Hu

Professor

The First Affiliated Hospital of University of Science and Technology of China

研究点 (1)

Loading locations...

相似试验